O. Ferchichi , O. Zidi , L. Mariem , A.A. Mohamed , I. Imen , A. Souha , W. Souissi , M. Rahma , S. Aouni , A. Sabra , A. Ben Halima , E. Bennour , I. Kammoun
{"title":"Heart failure therapeutic units: Prognostic impact","authors":"O. Ferchichi , O. Zidi , L. Mariem , A.A. Mohamed , I. Imen , A. Souha , W. Souissi , M. Rahma , S. Aouni , A. Sabra , A. Ben Halima , E. Bennour , I. Kammoun","doi":"10.1016/j.acvd.2024.10.042","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Heart failure (HF) continues to be a prevalent condition with high morbidity and mortality despite numerous therapeutic advances. Thus, we created a Heart Failure Therapeutic Unit (HFTU) to optimize medical treatment promptly.</div></div><div><h3>Objective</h3><div>Primary objective: to study the impact of the HFTU on reducing cardiovascular mortality and heart failure rehospitalizations at 1 year. Secondary objectives: to study the impact of the HFTU on treatment dose optimization and patient therapeutic adherence.</div></div><div><h3>Method</h3><div>We conducted a prospective, longitudinal, and single-center study at our cardiology department, with a follow-up period of 1 year. We included 159 patients with chronic HF (108 were included in the HFTU group and 51 in the control group). Patients included in the HFTU group received more frequent follow-up, early initiation of medical treatment with rapid progression to optimal doses, and transition to second-line treatments if there was no improvement and if indicated. The control group received standard care.</div></div><div><h3>Results</h3><div>The average age was 62.5<!--> <!-->±<!--> <!-->11.7 years, with a male predominance (80.5%), and a high prevalence of diabetes (44%); ischemic cardiomyopathy was the dominant etiology (57.9%), with a mean left ventricular ejection fraction (LVEF) of 31.6<!--> <!-->±<!--> <!-->8%. The most common inclusion criterion in the HFTU group was the absence of optimal medical treatment (97.2%). We observed a significant reduction in cardiovascular mortality and HF rehospitalizations at 1 year, as well as a significant decrease in HF rehospitalizations at 1 year in the UTIC group compared to the control group (15.7% vs 41.2%; <em>P</em> <!--><<!--> <!-->0.001; 11.1% vs 35.3%; <em>P</em> <!--><<!--> <!-->0.001 respectively), regardless of age, gender, and comorbidities (<em>P</em> <!--><<!--> <!-->0.001). Acquisition of optimal medical treatment (<em>P</em> <!--><<!--> <!-->0.001) and therapeutic adherence (<em>P</em> <!-->=<!--> <!-->0.015) were more frequent in the HFTU group. We noted an improvement in dyspnea (<em>P</em> <!-->=<!--> <!-->0.003), in LVEF (from<!--> <!-->≤<!--> <!-->40% to<!--> <!-->><!--> <!-->40%) (<em>P</em> <!--><<!--> <!-->0.001) and in heart rate control (HR<!--> <!--><<!--> <!-->70 bpm) (<em>P</em> <!--><<!--> <!-->0.001) in the HFTU group compared to the control group.</div></div><div><h3>Conclusion</h3><div>HFTU was associated with a significant reduction in the combined endpoint of cardiovascular mortality and heart failure rehospitalizations, as well as a decrease in heart failure rehospitalizations. Additionally, it was associated with more therapeutic optimization and adherence, and an improvement in symptoms, LVEF, and heart rate control.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 1","pages":"Page S44"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875213624003875","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Heart failure (HF) continues to be a prevalent condition with high morbidity and mortality despite numerous therapeutic advances. Thus, we created a Heart Failure Therapeutic Unit (HFTU) to optimize medical treatment promptly.
Objective
Primary objective: to study the impact of the HFTU on reducing cardiovascular mortality and heart failure rehospitalizations at 1 year. Secondary objectives: to study the impact of the HFTU on treatment dose optimization and patient therapeutic adherence.
Method
We conducted a prospective, longitudinal, and single-center study at our cardiology department, with a follow-up period of 1 year. We included 159 patients with chronic HF (108 were included in the HFTU group and 51 in the control group). Patients included in the HFTU group received more frequent follow-up, early initiation of medical treatment with rapid progression to optimal doses, and transition to second-line treatments if there was no improvement and if indicated. The control group received standard care.
Results
The average age was 62.5 ± 11.7 years, with a male predominance (80.5%), and a high prevalence of diabetes (44%); ischemic cardiomyopathy was the dominant etiology (57.9%), with a mean left ventricular ejection fraction (LVEF) of 31.6 ± 8%. The most common inclusion criterion in the HFTU group was the absence of optimal medical treatment (97.2%). We observed a significant reduction in cardiovascular mortality and HF rehospitalizations at 1 year, as well as a significant decrease in HF rehospitalizations at 1 year in the UTIC group compared to the control group (15.7% vs 41.2%; P < 0.001; 11.1% vs 35.3%; P < 0.001 respectively), regardless of age, gender, and comorbidities (P < 0.001). Acquisition of optimal medical treatment (P < 0.001) and therapeutic adherence (P = 0.015) were more frequent in the HFTU group. We noted an improvement in dyspnea (P = 0.003), in LVEF (from ≤ 40% to > 40%) (P < 0.001) and in heart rate control (HR < 70 bpm) (P < 0.001) in the HFTU group compared to the control group.
Conclusion
HFTU was associated with a significant reduction in the combined endpoint of cardiovascular mortality and heart failure rehospitalizations, as well as a decrease in heart failure rehospitalizations. Additionally, it was associated with more therapeutic optimization and adherence, and an improvement in symptoms, LVEF, and heart rate control.
期刊介绍:
The Journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles and editorials. Topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.